Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
Author:
Affiliation:
1. Department of Pharmacythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
2. Department of Medical AdministrationChengdu Women's and Children's Central Hospital Chengdu China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3169
Reference33 articles.
1. Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
2. Development of SGLT1 and SGLT2 inhibitors
3. SGLT inhibitor adjunct therapy in type 1 diabetes
4. Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
5. Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes;Diabetes Research and Clinical Practice;2024-01
2. Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review;Frontiers in Endocrinology;2023-12-19
3. Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials;Primary Care Diabetes;2023-11
4. Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial;Journal of Diabetes Science and Technology;2023-05-25
5. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies;Frontiers in Bioscience-Landmark;2023-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3